Scholarlink

<p>Secondary metabolites from the marine bacterium <i>Stenotrophomonas rhizophila</i> strain BGNAK1 were evaluated for neuroprotective activity using biochemical and cellular assays relevant to Alzheimer’s disease. The crude extract exhibited significant acetylcholinesterase (AChE) inhibitory activity with an IC₅₀ value of 106.0163&#xa0;µg/mL, indicating effective modulation of cholinergic function. Antioxidant evaluation revealed strong free radical scavenging capacity, with DPPH radical inhibition of and 97% at 1.0&#xa0;mg/ml. The extract also significantly reduced intracellular reactive oxygen species levels, showing a reduction compared to untreated control cells at the highest tested concentration. Cytotoxicity analysis using PC12 and SH-SY5Y neuroblastoma cell lines demonstrated <b>&gt;</b> 85% cell viability across all tested concentrations, confirming good biocompatibility. No significant morphological alterations or growth inhibition were observed under treatment conditions. Overall, these results demonstrate that metabolites derived from <i>S. rhizophila</i> BGNAK1 exert multi-target neuroprotective effects through combined cholinesterase inhibition and antioxidant mechanisms. Although direct neuronal injury models were not employed, the integrated biochemical and cellular findings provide quantitative evidence supporting the neurotherapeutic potential of marine bacterial metabolites and justify further investigation into their role in Alzheimer’s disease-oriented drug discovery.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neuroprotective potential of a novel marine metabolite from S. rhizophila BGNAK1 targeting acetylcholinesterase in Alzheimer’s disease

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Akash Karthikeyan,
  • Nigina Gopinath,
  • Navami Krishna,
  • Abey Joseph,
  • Rajanikant G Krishnamurthy,
  • Baiju G Nair

摘要

Secondary metabolites from the marine bacterium Stenotrophomonas rhizophila strain BGNAK1 were evaluated for neuroprotective activity using biochemical and cellular assays relevant to Alzheimer’s disease. The crude extract exhibited significant acetylcholinesterase (AChE) inhibitory activity with an IC₅₀ value of 106.0163 µg/mL, indicating effective modulation of cholinergic function. Antioxidant evaluation revealed strong free radical scavenging capacity, with DPPH radical inhibition of and 97% at 1.0 mg/ml. The extract also significantly reduced intracellular reactive oxygen species levels, showing a reduction compared to untreated control cells at the highest tested concentration. Cytotoxicity analysis using PC12 and SH-SY5Y neuroblastoma cell lines demonstrated > 85% cell viability across all tested concentrations, confirming good biocompatibility. No significant morphological alterations or growth inhibition were observed under treatment conditions. Overall, these results demonstrate that metabolites derived from S. rhizophila BGNAK1 exert multi-target neuroprotective effects through combined cholinesterase inhibition and antioxidant mechanisms. Although direct neuronal injury models were not employed, the integrated biochemical and cellular findings provide quantitative evidence supporting the neurotherapeutic potential of marine bacterial metabolites and justify further investigation into their role in Alzheimer’s disease-oriented drug discovery.